BOLD Stock Overview
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Boundless Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.35 |
| 52 Week High | US$15.24 |
| 52 Week Low | US$8.53 |
| Beta | 0 |
| 1 Month Change | -29.27% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.4% | 4.4% | 0.6% |
| 1Y | n/a | 2.8% | 23.9% |
Return vs Industry: Insufficient data to determine how BOLD performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BOLD performed against the US Market.
Price Volatility
| BOLD volatility | |
|---|---|
| BOLD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BOLD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BOLD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 72 | Zach Hornby | boundlessbio.com |
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA.
Boundless Bio, Inc. Fundamentals Summary
| BOLD fundamental statistics | |
|---|---|
| Market cap | US$207.92m |
| Earnings (TTM) | -US$49.43m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs BOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$49.43m |
| Earnings | -US$49.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BOLD perform over the long term?
See historical performance and comparison